A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

THU0042 Preclinical Characterization of Sirukumab, a Human Monoclonal Antibody that Targets Human Interleukin-6 Signaling

(2015) D. Gardner et al.   ANNALS OF THE RHEUMATIC DISEASES

Biologic Therapy in Lupus Nephritis

(2015) Frédéric A. Houssiau   NEPHRON CLINICAL PRACTICE

Lupus Nephritis: From Pathogenesis to Targets for Biologic Treatment

(2015) Yujuan Liu et al.   NEPHRON CLINICAL PRACTICE

Lupus Nephritis: The Evolving Role of Novel Therapeutics

(2014) Brad H. Rovin et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients

(2014) AS Alvarado et al.   LUPUS

Interleukin-6 in renal disease and therapy

(2014) S. A. Jones et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus

(2013) C. C. Mok et al.   ARTHRITIS AND RHEUMATISM

Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities

(2013) Jürgen Scheller et al.   SEMINARS IN IMMUNOLOGY

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study

(2013) Richard Furie et al.   Arthritis & Rheumatology

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis

(2012) D-Y Chen et al.   LUPUS

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months

(2012) Z. Touma et al.   RHEUMATOLOGY

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

(2011) Zhenhua Xu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

(2010) T. Puchalski et al.   CLINICAL CANCER RESEARCH

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

(2010) Jasmine P. Davda et al.   mAbs

Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus

(2009) H. CASH et al.   JOURNAL OF RHEUMATOLOGY

A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis

(2009) Derek M. Fine et al.   KIDNEY INTERNATIONAL